Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-C2: Neoadjuvant Chemotherapy +/- Radiotherapy and Serplulimab in Locally Advanced Colon Cancer
NCT07877597Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in colon cancer, sponsored by Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07877597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877597.